Press Release

  View printer-friendly version
<< Back
Dextera Surgical Hosts Hands-on Training Course for Video-Assisted Thoracic Surgery Techniques Using MicroCutter 5/80™ for Segmentectomy

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 27, 2017-- Dextera Surgical Inc. (Nasdaq: DXTR), a company developing and commercializing the MicroCutter 5/80™ Stapler, today announced that it sponsored an international hands-on training course for thoracic surgeons from across Europe focused on advanced techniques for video-assisted thoracic surgery (VATS).

During this day-long event in Tubingen, Germany, a faculty of world-leading thoracic surgeons taught advanced techniques which included the use of the MicroCutter 5/80™ in VATS for anatomical segmentectomy procedures. A segmentectomy is a procedure that removes a portion of a lobe of the lungs (typically comprised of two or more segments) rather than the entire lobe. Segmentectomy procedures require precision in stapling, as the operating area is tightly confined and the vessels are difficult to access.

New advances in lung cancer diagnoses are enabling earlier diagnosis and therefore earlier treatments for patients with lung cancer. Increasingly, segmentectomy rather than a traditional lobectomy is considered as a viable treatment for early-stage lung cancer which preserves more lung tissue than a complete lobectomy.

“The MicroCutter 5/80 is an ideal tool for VATS lobectomy and especially for segmentectomy as it enables less tissue dissection and allows me to maneuver more effectively within the patient’s chest,” said PD Dr. Med. Volker Steger of the University of Tubingen, Germany. “We appreciate Dextera’s support for this international training course.”

“We believe these courses, where surgeons learn cutting-edge surgical techniques for VATS procedures, are critically important to demonstrate how the MicroCutter 5/80’s small size and wider articulation help to enable adoption of less invasive surgical approaches for these technically challenging procedures,” said Liam Burns, vice president of worldwide sales and marketing for Dextera Surgical.

MicroCutter Indication Information

In the United States, the MicroCutter 5/80 Stapler and MicroCutter 30 White, Blue and Curved Tip White and Blue Reloads are intended for transection and resection in multiple open or minimally invasive urologic, thoracic, and pediatric surgical procedures, as well as application for transection, resection, and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. With the recent clearance, the MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip White Reloads may additionally be used in conjunction with open solid organ parenchymal dissection techniques on veins four to five millimeters in diameter and arteries three to seven millimeters in diameter.

About Dextera Surgical

Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.

Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.

Forward-Looking Statements

The statements in this press release regarding the beneficial use of the MicroCutter 5/80 during segmentectomy procedures are "forward-looking statements." There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including the risks detailed from time to time in Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, under the caption “Risk Factors.” Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at

Source: Dextera Surgical Inc.

Dextera Surgical Inc.
Bob Newell, 650-331-7133
Vice President, Finance and Chief Financial Officer